Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
| ▸ | IL2 | P60568 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25835943 | 0.92 | DRD2 (0.37) | DRD2CRBNHDAC6OPRM1LGALS3 | |
| SCHEMBL25836299 | 0.83 | DRD2 (0.38) | DRD2CRBNHDAC6OPRM1LGALS3 | |
| SCHEMBL26033173 | 0.81 | DRD2 (0.34) | DRD2HDAC6OPRM1TTRIL2 | |
| SCHEMBL26033618 | 0.81 | DRD2 (0.36) | DRD2CRBNHDAC6OPRM1LGALS3 | |
| SCHEMBL26032130 | 0.78 | DRD2 (0.36) | DRD2CRBNHDAC6OPRM1LGALS3 | |
| SCHEMBL25835923 | 0.77 | POLB (0.33) | — | |
| SCHEMBL25835936 | 0.70 | DRD2 (0.42) | DRD2OPRM1 | |
| SCHEMBL25835937 | 0.70 | DRD2 (0.42) | DRD2OPRM1LGALS3 | |
| SCHEMBL26033158 | 0.70 | POLB (0.40) | — | |
| SCHEMBL25835917 | 0.69 | POLB (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | DRD2 4154/4885CRBN 2964/4885HDAC6 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.